Yanan Zhu
Stock Analyst at Wells Fargo
(1.91)
# 3,324
Out of 4,853 analysts
64
Total ratings
30.77%
Success rate
-3.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGX Metagenomi | Maintains: Overweight | $20 → $16 | $1.66 | +863.86% | 3 | May 14, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $50 → $45 | $11.91 | +277.83% | 7 | May 14, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Equal-Weight | $1.5 → $1 | $0.29 | +249.77% | 3 | May 14, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $115 → $100 | $39.21 | +155.04% | 2 | May 8, 2025 | |
| BEAM Beam Therapeutics | Maintains: Overweight | $75 → $70 | $17.00 | +311.76% | 3 | May 7, 2025 | |
| RGLS Regulus Therapeutics | Downgrades: Equal-Weight | $9 | $8.10 | +11.11% | 2 | May 1, 2025 | |
| AUTL Autolus Therapeutics | Maintains: Overweight | $8 → $6 | $2.26 | +165.49% | 3 | Mar 21, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Overweight | $12 → $10 | $3.30 | +203.03% | 2 | Mar 12, 2025 | |
| FATE Fate Therapeutics | Maintains: Equal-Weight | $5 → $4 | $1.34 | +198.51% | 3 | Mar 6, 2025 | |
| QURE uniQure | Maintains: Equal-Weight | $35 → $30 | $16.61 | +80.61% | 2 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $50 | $7.58 | +559.63% | 4 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $7 → $4 | $1.80 | +122.22% | 6 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $4 | $1.02 | +292.16% | 4 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $82 → $77 | $35.24 | +118.50% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $40 | $16.59 | +141.18% | 2 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $70 → $65 | $38.57 | +68.52% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $3.62 | +728.73% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $25 | $1.80 | +1,288.89% | 4 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $35.59 | +40.49% | 3 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $0.49 | +713.01% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $2.71 | +16,505.17% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $10 | $2.88 | +247.22% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $579.33 | -43.73% | 1 | Feb 2, 2021 | |
Metagenomi
May 14, 2025
Maintains: Overweight
Price Target: $20 → $16
Current: $1.66
Upside: +863.86%
Arcturus Therapeutics Holdings
May 14, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $11.91
Upside: +277.83%
Adaptimmune Therapeutics
May 14, 2025
Maintains: Equal-Weight
Price Target: $1.5 → $1
Current: $0.29
Upside: +249.77%
Sarepta Therapeutics
May 8, 2025
Maintains: Overweight
Price Target: $115 → $100
Current: $39.21
Upside: +155.04%
Beam Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $17.00
Upside: +311.76%
Regulus Therapeutics
May 1, 2025
Downgrades: Equal-Weight
Price Target: $9
Current: $8.10
Upside: +11.11%
Autolus Therapeutics
Mar 21, 2025
Maintains: Overweight
Price Target: $8 → $6
Current: $2.26
Upside: +165.49%
Voyager Therapeutics
Mar 12, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: $3.30
Upside: +203.03%
Fate Therapeutics
Mar 6, 2025
Maintains: Equal-Weight
Price Target: $5 → $4
Current: $1.34
Upside: +198.51%
uniQure
Feb 28, 2025
Maintains: Equal-Weight
Price Target: $35 → $30
Current: $16.61
Upside: +80.61%
Feb 28, 2025
Maintains: Overweight
Price Target: $60 → $50
Current: $7.58
Upside: +559.63%
Dec 11, 2024
Downgrades: Equal-Weight
Price Target: $7 → $4
Current: $1.80
Upside: +122.22%
Nov 12, 2024
Maintains: Overweight
Price Target: $17 → $4
Current: $1.02
Upside: +292.16%
Nov 7, 2024
Maintains: Overweight
Price Target: $82 → $77
Current: $35.24
Upside: +118.50%
May 13, 2024
Maintains: Overweight
Price Target: $35 → $40
Current: $16.59
Upside: +141.18%
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $38.57
Upside: +68.52%
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $3.62
Upside: +728.73%
Mar 1, 2024
Maintains: Overweight
Price Target: $22 → $25
Current: $1.80
Upside: +1,288.89%
Jan 3, 2024
Reiterates: Overweight
Price Target: $50
Current: $35.59
Upside: +40.49%
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $0.49
Upside: +713.01%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $2.71
Upside: +16,505.17%
Jan 4, 2023
Maintains: Overweight
Price Target: $14 → $10
Current: $2.88
Upside: +247.22%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $579.33
Upside: -43.73%